Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialMichel Seymour, Philip Quirke, Susan D. Richman et al.|The Lancet Oncology|2013Cited by 392
<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp>, <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trialsSusan D. Richman, Philip Quirke, Katie Southward et al.|The Journal of Pathology|2015Cited by 238